ESR1 and breast carcinoma: Therefore, ERα antagonists, for example, tamoxifen and fulvestrant, and aromatase inhibitors (AIs) that block the ER signalling are widely used in endocrine therapies for ERα-positive (ERα+) breast cancer patients1, 2, 3.